MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug

Core Insights - MetaVia Inc. has announced a strong global intellectual property portfolio for its lead asset, DA-1726, which is aimed at treating obesity and related metabolic disorders, securing 39 granted and pending patents that extend protection until 2041 [1][2] Company Performance - The company's CEO highlighted the significance of the intellectual property, emphasizing the unique design of DA-1726 as a dual GLP-1/glucagon agonist, with recent clinical data showing a 9% weight loss at the 48 mg dose and improvements in waist size and blood sugar levels [2] - MetaVia's stock is currently trading 21.8% below its 20-day simple moving average and 77.6% below its 200-day SMA, indicating significant bearish pressure, with shares down 90.85% over the past 12 months [3] - The stock's RSI is at 23.34, suggesting it may be undervalued and could rebound, while the MACD indicates potential bullish momentum despite the overall bearish trend [4] Sector Comparison - MetaVia is outperforming its sector with a gain of approximately 10.2%, while the Healthcare sector has only increased by 0.17%, reflecting a significant deviation from recent sector trends [5] - The Healthcare sector has seen a slight decline of 1.18% over the past 30 days but has gained 2.83% over the last 90 days, indicating mid-tier performance in the market [5] Analyst Consensus - The stock carries a Buy Rating, with recent analyst actions including HC Wainwright & Co. raising the target price to $40.00 [6] - At the time of publication, MetaVia shares were up 9.64% at $1.84, trading near its 52-week low of $1.61, with key resistance at $2.00 and support at $1.50 [6]